FFAR1 and type 2 diabetes mellitus: Numerous GPR40 agonists have been generated to increase insulin production from β-cells exposed to hyperglycemia in vivo, and reports this far provide some proof of concept for GPR40 agonists as a treatment for type 2 diabetes (35).